Filius Bart purchased $258K of PRQR
Filius Bart purchased 150,000 shares of ProQR Therapeutics N.V. (PRQR) at $1.72 ($0.26M total) on 2026-07-17.
How this was made
The 30-second read
Why it matters
The newest fact is the disclosed open-market purchase of 150,000 shares at $1.7195/share, which may slightly influence sentiment but does not change fundamentals on its own.
Market read
Traders may monitor for follow-on insider activity, but the filing alone is unlikely to drive a sustained repricing without additional company catalysts.
What to watch
The article does not state whether the purchase was part of a broader pattern, the insider’s prior cost basis, or any concurrent company developments that would make the trade more informative.
Background
This is an SEC Form 4 insider transaction for ProQR Therapeutics N.V., reported by director Filius Bart.
Ticker impact
Director Filius Bart bought 150,000 shares of ProQR Therapeutics at $1.7195/share, totaling about $257,925, per Form 4 filed July 21.
Likely limited near-term impact; any effect is more sentiment-driven than valuation-changing.
Form 4 insider buys can be read as confidence, but the article provides no accompanying operational update, guidance, or material corporate event.
Market effects
Minimal; this is company-specific insider activity with no sector-wide regulatory or clinical signal included.
None indicated; no broader market or regional catalyst described.
None indicated; the disclosure is limited to a single insider transaction.
Counterpoint
Insider buys can be routine or tax/portfolio-driven, and the absence of a 10b5-1 plan does not guarantee a strong informational signal.
Key entities
- issuerProQR Therapeutics N.V.
Subject of the Form 4 insider transaction; ticker PRQR.
- insiderFilius Bart
Director who purchased 150,000 shares for about $257,925.